Connor, Clark & Lunn Investment Management (CC&L)
EGRX

Connor, Clark & Lunn Investment Management (CC&L)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-9,309
Closed -$264K – 1547
2023
Q1 		$264K Buy
+9,309
New +$276K ﹤0.01% 1035
2020
Q3 		– Sell
-5,251
Closed -$252K – 1159
2020
Q2 		$252K Buy
+5,251
New +$262K ﹤0.01% 867
2020
Q1 		– Sell
-6,250
Closed -$376K – 1200
2019
Q4 		$376K Sell
6,250
-24,483
-80% -$1.46M ﹤0.01% 723
2019
Q3 		$1.74M Sell
30,733
-8,185
-21% -$460K 0.01% 435
2019
Q2 		$2.17M Buy
38,918
+150
+0.4% +$7.82K 0.01% 420
2019
Q1 		$1.96M Buy
38,768
+1,575
+4% +$70.1K 0.01% 414
2018
Q4 		$1.5M Sell
37,193
-3,100
-8% -$160K 0.01% 468
2018
Q3 		$2.79M Buy
40,293
+300
+0.8% +$22.7K 0.02% 391
2018
Q2 		$3.03M Sell
39,993
-6,432
-14% -$405K 0.02% 395
2018
Q1 		$2.45M Buy
46,425
+11,400
+33% +$663K 0.01% 365
2017
Q4 		$1.87M Buy
35,025
+12,725
+57% +$708K 0.01% 426
2017
Q3 		$1.33M Buy
+22,300
New +$1.35M 0.01% 488

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s EGRX Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 9,309 shares — an estimated $264K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in EGRX in Q3 2017 and held it in 12 quarters. The position peaked at $3.03M in Q2 2018. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 9,309 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $264K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Eagle Pharmaceuticals, Inc. position peaked at $3.03M in Q2 2018.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.